161 related articles for article (PubMed ID: 6390963)
21. [Role of the blood kinin system in the course of the reparation processes in tuberculosis].
Makinskiĭ AI; Solov'eva IP
Vrach Delo; 1986 Dec; (12):78-80. PubMed ID: 3548065
[No Abstract] [Full Text] [Related]
22. [Pathogenetic treatment of patients with disseminated neurodermatitis using the specific antikinin preparation parmidin].
Grebennikov VA
Sov Med; 1983; (1):44-7. PubMed ID: 6836389
[No Abstract] [Full Text] [Related]
23. [Effect of tuberculin on the clinical course and healing processes in experimental tuberculosis].
Krylov VA; Titov VF; Tereshin VS
Probl Tuberk; 1994; (4):41-4. PubMed ID: 7984615
[TBL] [Abstract][Full Text] [Related]
24. [Effect of kinin system inhibitors and stimulants on the course of tuberculosis and the healing processes in an experiment].
Puzik VI; Uvarova OA; Zemskova ZS; Kaminskaia GO; Gedymin LE
Probl Tuberk; 1983 May; (5):52-6. PubMed ID: 6191323
[No Abstract] [Full Text] [Related]
25. [Effect of combinations of trace elements and vitamins in inositol metabolism and the morphohistochemical indices in the isoniazid treatment of experimental tuberculosis].
Sodikov ES; Gapon'ko LA
Probl Tuberk; 1976 Jul; (7):75-9. PubMed ID: 959204
[No Abstract] [Full Text] [Related]
26. [Experimental study of the anti-inflammatory action of pyridinolcarbamate].
Shvarts GIa; Liberman SS; Mashkovskiĭ MD; Berliand EA
Farmakol Toksikol; 1975; 38(4):434-6. PubMed ID: 1213130
[TBL] [Abstract][Full Text] [Related]
27. Diabetic microangiopathy in KK mice. II. Suppression of Glomerulosclerosis by pyridinolcarbamate.
Reddi AS; Oppermann W; Velasco CA; Camerini-Davalos RA
Exp Mol Pathol; 1977 Apr; 26(2):325-39. PubMed ID: 852540
[No Abstract] [Full Text] [Related]
28. [Therapeutic properties of a prolonged-action preparation of isoniazid].
Ivaniuta OM; Maliuk VI; Sokirko TA; Klimenko MT; Suslov EI
Probl Tuberk; 1988; (3):47-50. PubMed ID: 3387395
[No Abstract] [Full Text] [Related]
29. [Effect of levamisole on the immunological reactivity of mice infected with tuberculosis].
Chumak AA; Kostromin AP
Probl Tuberk; 1981 Oct; (10):58-62. PubMed ID: 7312855
[No Abstract] [Full Text] [Related]
30. [Role of physiologically active substances in the pathogenesis and therapy of atherosclerosis].
Klimov AN
Vestn Akad Med Nauk SSSR; 1976; (9):48-50. PubMed ID: 1020445
[No Abstract] [Full Text] [Related]
31. [Regulation of the activity of the blood kinin system as a method for the pathogenetic therapy of pulmonary tuberculosis].
Priĭmak AA; Makinskiĭ AI
Vrach Delo; 1985 Oct; (10):95-7. PubMed ID: 3841435
[No Abstract] [Full Text] [Related]
32. The effect of Prodectin (pyridinolcarbamate) treatment of the circulation rate in obliterating arterial diseases of the lower extremities.
Fényes G; Gótzy G; Fehrentheil L
Ther Hung; 1975; 23(2):64-66. PubMed ID: 1188705
[No Abstract] [Full Text] [Related]
33. Pyridinolcarbamate in the long-term treatment of ischaemic heart disease.
Gulyás A; Szám I
Ther Hung; 1976; 24(2):63-6. PubMed ID: 982341
[No Abstract] [Full Text] [Related]
34. [Mechanism of action and clinical effectiveness of the new Soviet-made drug parmidin in the treatment of arteriosclerosis and ischemic heart disease].
Kukes VG; Mashkovskiĭ MD; Paskhina TS; Borisov VG; Shvarts GIa
Kardiologiia; 1978 Oct; 18(10):61-8. PubMed ID: 213636
[TBL] [Abstract][Full Text] [Related]
35. [Clinical evaluation of pyridinolcarbamate effect on patients with obliterating atherosclerosis (author's transl)].
Roztocil K; Oliva I; Linhart J; Prerovský I; Modr Z
Cas Lek Cesk; 1976 Aug; 115(33-34):1051-5. PubMed ID: 975177
[No Abstract] [Full Text] [Related]
36. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
37. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis.
Ena J; Valls V
Clin Infect Dis; 2005 Mar; 40(5):670-6. PubMed ID: 15714411
[TBL] [Abstract][Full Text] [Related]
38. [Preliminary study on isoniazid-epiroprim combination in a tuberculosis murine model].
N'guessan K; Dosso M; Marchal G; Chavarot P; Romain F; Pescher P; Edy
Bull Soc Pathol Exot; 2002 Nov; 95(4):265-8. PubMed ID: 12596375
[TBL] [Abstract][Full Text] [Related]
39. [Therapeutic results with combination of pyridinolcarbamate and clofibrate in atherosclerotic patients].
Valiensi M; Riboli E; Lombardi M
Minerva Cardioangiol; 1976 Feb; 24(2):148-54. PubMed ID: 1256654
[No Abstract] [Full Text] [Related]
40. [The importance of pyridinolcarbamate and clofibrate association in the treatment of arteriosclerosis].
Pola P
Minerva Cardioangiol; 1975 Apr; 23(4):261-9. PubMed ID: 1095958
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
